Eighteen months after his initial diagnosis, chemotherapy hadn’t slowed 21-year-old Mason Henderson’s rare brain tumor, which ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab and Daiichi Sankyo (4568.T), opens new tab have withdrawn their US application seeking accelerated approval for an experimental lung cancer therapy, ...

Moderna’s AI reads a patient’s own tumor, decides which mutations to target and builds a treatment that exists nowhere else. The therapy delivered the first positive Phase 3 result for a cancer ...

RAHWAY, N.J.- Merck is trimming its payroll again. The pharmaceutical giant, with headquarters in Rahway, New Jersey, has filed a notice in accordance with the state's WARN Act, indicating that it ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors. Unlike ...

NOW PLAYING Investors Are Rotating Into Healthcare. Here's Why. Not so fast, say analysts. Leerink Partners analyst Daina Graybosch says the reception was "overly optimistic and creates expectations ...

Moderna and Merck have announced that a personalised mRNA cancer vaccine called Intismeran reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field ...

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the ...

Merck MRK.N and Moderna MRNA.O said on Wednesday a study of a personalized mRNA vaccine combined with the immunotherapy drug Keytruda reduced melanoma skin cancer recurrence and spread compared with ...

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients. By Carolyn Y. Johnson An experimental mRNA vaccine allowed people with high ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial, raising expectations for a potential life-extending treatment ...